Browsing Tag
Eli Lilly and Company
141 posts
Walmart (NYSE: WMT) expands GLP-1 support as retail healthcare competition moves beyond the prescription counter
Walmart is expanding GLP-1 support with virtual care, nutrition, and pharmacy access. Read why this could deepen its healthcare moat.
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
From Eli Lilly to Hims & Hers: what Kathryn Beiser’s move says about the telehealth platform’s ambitions
Hims & Hers Health appoints Kathryn Beiser as Chief Communications Officer. Explore what the move signals about strategy, growth, and investor sentiment.
Why Eli Lilly’s Zepbound just tightened its grip on the obesity drug market in 2026
Find out how Eli Lilly and Company is strengthening Zepbound’s market dominance with a multi-dose KwikPen and reshaping obesity drug access in 2026.
Can Eli Lilly and Company’s Omvoh reset expectations for long-term Crohn’s disease control?
Three-year Omvoh data shows durable steroid-free remission in Crohn’s disease. Read how this reshapes Eli Lilly and Company’s long-term strategy.
Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes
Eli Lilly and Company is ramping inventory ahead of a key FDA decision on its oral weight loss pill. Find out what this signals for obesity drugs and investors.
Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy
Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy.
Lilly selects Lehigh Valley, Pennsylvania for obesity drug manufacturing plant
Lilly is building a $3.5B injectable medicine facility in Pennsylvania to scale retatrutide. Find out how this reshapes the obesity drug market and U.S. supply.
Eli Lilly blocked in European heart failure label push: Is the GLP‑1 race now tilting to Novo Nordisk?
Find out why Eli Lilly’s bid to expand Mounjaro’s EU label for heart failure was declined and what it means for the company’s growth strategy and competitive standing.
Can weight loss drugs cause fatal pancreas illness? UK raises red flag on GLP-1 therapies
UK strengthens pancreatitis risk warning for GLP-1 weight loss and diabetes drugs like Wegovy and Mounjaro. Find out what it means for health systems and pharma.